医学
肺癌
药品
药物反应
肿瘤科
癌症
靶向治疗
内科学
重症监护医学
药理学
作者
Sunshin Kim,Youngjoo Lee,Bo Song,Hanna Sim,Eun Hye Kang,Mihwa Hwang,Namhee Yu,Seok Jin Hong,Charny Park,Beung‐Chul Ahn,Eic Ju Lim,Kum Hui Hwang,Seog-Yun Park,Jin Ho Choi,Geon Kook Lee,Ji‐Youn Han
出处
期刊:Cancers
[MDPI AG]
日期:2024-02-14
卷期号:16 (4): 778-778
标识
DOI:10.3390/cancers16040778
摘要
Intratumor heterogeneity leads to different responses to targeted therapies, even within patients whose tumors harbor identical driver oncogenes. This study examined clinical outcomes according to a patient-derived cell (PDC)-based drug sensitivity test in lung cancer patients treated with targeted therapies. From 487 lung cancers, 397 PDCs were established with a success rate of 82%. In 139 PDCs from advanced non-small-cell lung cancer (NSCLC) patients receiving targeted therapies, the standardized area under the curve (AUC) values for the drugs was significantly correlated with their tumor response (p = 0.002). Among 59 chemo-naive EGFR/ALK-positive NSCLC patients, the PDC non-responders showed a significantly inferior response rate (RR) and progression-free survival (PFS) for the targeted drugs than the PDC responders (RR, 25% vs. 78%, p = 0.011; median PFS, 3.4 months [95% confidence interval (CI), 2.8–4.1] vs. 11.8 months [95% CI, 6.5–17.0], p < 0.001). Of 25 EGFR-positive NSCLC patients re-challenged with EGFR inhibitors, the PDC responder showed a higher RR than the PDC non-responder (42% vs. 15%). Four patients with wild-type EGFR or uncommon EGFR-mutant NSCLC were treated with EGFR inhibitors based on their favorable PDC response to EGFR inhibitors, and two patients showed dramatic responses. Therefore, the PDC-based drug sensitivity test results were significantly associated with clinical outcomes in patients with EGFR- or ALK-positive NSCLC. It may be helpful for predicting individual heterogenous clinical outcomes beyond genomic alterations.
科研通智能强力驱动
Strongly Powered by AbleSci AI